- Conditions
- Knee Osteoarthritis
- Interventions
- Diet, Exercise
- Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- College Station, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 133
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vitamin D Status
- Interventions
- Not listed
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor
- Interventions
- EMB-01
- Drug
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Urothelial Carcinoma
- Interventions
- Gemcitabine and Cisplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Hartford, Connecticut • Basking Ridge, New Jersey + 6 more
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinate
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more
- Conditions
- Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
- Interventions
- disitamab vedotin, tucatinib
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 77
- States / cities
- Tucson, Arizona • Orange, California • San Francisco, California + 39 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Anti-Transforming Growth Factor-beta (GC 1008)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Little Brunswick, New Jersey
- Conditions
- Colorectal Carcinoma, Gastric Carcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- BI 765049
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 1 more
- Conditions
- Neoplasms
- Interventions
- Remzistotug, Dostarlimab, Belrestotug, Nelistotug, GSK5764227
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- San Francisco, California • Charlotte, North Carolina • Oklahoma City, Oklahoma + 4 more
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
- Interventions
- RGX-314
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 8
- States / cities
- Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
- Conditions
- White Spot Lesion, Orthodontic Treatment, Decalcification; Teeth
- Interventions
- Clinpro™ 5000, Clinpro™ Tooth Crème, MI-Paste Plus
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Glycogen Storage Disease Type IA
- Interventions
- DTX401, Placebo, Oral prednisolone, Placebo for oral prednisolone
- Genetic · Other · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 9
- States / cities
- Orange, California • Aurora, Colorado • Farmington, Connecticut + 6 more
- Conditions
- Leukodystrophy, Globoid Cell
- Interventions
- PBKR03
- Biological
- Lead sponsor
- Gemma Biotherapeutics
- Industry
- Eligibility
- 1 Month to 9 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
- Interventions
- S095029, pembrolizumab 200 mg (KEYTRUDA ®)
- Drug
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Ocala, Florida • Noblesville, Indiana • Houston, Texas
- Conditions
- Severe Combined Immunodeficiency
- Interventions
- Gene-Transduced Autologous CD34+ Stem Cells
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Months to 20 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Myositis Associated Interstitial Lund Disease (MA-ILD)
- Interventions
- Nintedanib, Placebo, Standard of Care
- Drug
- Lead sponsor
- Rohit Aggarwal, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- FLOT, FOLFOX, FOLFIRI, FOLFIRINOX, PACLITAXEL with or without CARBOPLATIN, DOCETAXEL and IRINOTECAN (alone or combined), NIVOLUMAB (alone or when added to a regimen above), PEMBROLIZUMAB (alone or when added to a regimen above), Durvalumab, Trastuzumab
- Combination Product · Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Limb-girdle Muscular Dystrophy, Becker Muscular Dystrophy
- Interventions
- Prednisone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV Prevention, Pre-exposure Prophylaxis, STI
- Interventions
- Health service - home-based PrEP monitoring
- Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumors, MET Gene Alterations
- Interventions
- elzovantinib (TPX-0022)
- Drug
- Lead sponsor
- Turning Point Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • Orange, California • Denver, Colorado + 8 more
- Conditions
- Alzheimer Disease, Early Onset Alzheimer Disease
- Interventions
- LX1001
- Biological
- Lead sponsor
- Lexeo Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- Maitland, Florida • Orlando, Florida • New York, New York + 1 more
- Conditions
- Giant Cell Arteritis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Decipher® Testing
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 3
- States / cities
- Bay Pines, Florida • Tampa, Florida